Anabolic treatments in bovines: quantification of plasma protein markers of dexamethasone administration
- PMID: 34133848
- DOI: 10.1002/pmic.202000238
Anabolic treatments in bovines: quantification of plasma protein markers of dexamethasone administration
Abstract
The aim of this study was to profile plasma proteome responses in bulls experimentally treated with dexamethasone at anabolic dosage. Illicit use of active substances in animal husbandry remains a matter of concern in Europe. Corticosteroids are probably one of the most widespread growth promoter family illegally used in beef cattle and veal calves. Testing for corticosteroids relies on detection of drug residues or their metabolites in biological fluids or tissues. Their indirect detection by mapping altered physiological parameters may overcome limits linked to route of administration, dosage, biotransformation and elimination kinetics that can lower residual drug concentration, hampering official controls. A set of 11 proteins proposed in literature as potential markers of anabolic treatments with dexamethasone, was quantified in bovine plasma by targeted proteomics based on liquid chromatography-high resolution tandem mass spectrometry. Among investigated proteins, sex hormone-binding globulin (SHBG), histidine-rich glycoprotein (HRG) and paraoxonase-1 (PON1) were found to be biomarkers of treatment. To investigate further such biomarkers, an additional group of veal calves was experimentally treated with dexamethasone at anabolic. These animals also demonstrated a significant alteration in SHBG, HRG and PON1 concentration, suggesting that quantification of plasma markers have the potential to detect animals illegally exposed to dexamethasone.
Keywords: anabolic treatment; bovine; dexamethasone; mass spectrometry; plasma; proteomics.
© 2021 Wiley-VCH GmbH.
References
REFERENCES
-
- C. D. 96/22/EC. (1996). Council Directive 96/22/EC of 29 April 1996 concerning the prohibition on the use in stockfarming of certain substances having a hormonal or thyrostatic action and of β-agonists, and repealing Directives 81/602/EEC, 88/146/EEC and 88/299/EEC. Official Journal of the European Communities, L125, 3.
-
- Courtheyn, D., Le Bizec, B., Brambilla, G., De Brabander, H. F, Cobbaert, E., Van De Wiele, M., Vercammen, J., & De Wasch, K., (2002). Recent developments in the use and abuse of growth promoters. Analytica Chimica Acta, 473, 71-82.
-
- Stephany, R. W. (2010). Hormonal growth promoting agents in food producing animals. Handbook of Experimental Pharmacology, 195, 355-367.
-
- Tang, C., Zhang, K., Liang, X., Zhao, Q., & Zhang, J. (2016). Application of a NMR-based untargeted quantitative metabonomic approach to screen for illicit salbutamol administration in cattle. Analytical and Bioanalytical Chemistry, 408, 4777-4783.
-
- Dervilly-Pinel, G., Royer, A. -. L., Bozzetta, E., Pezzolato, M., Herpin, L., Prevost, S., & Le Bizec, B. (2018). When LC-HRMS metabolomics gets ISO17025 accredited and ready for official controls âapplication to the screening of forbidden compounds in livestock. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 35, 1948-1958.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous